HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Once Was Enough For J&J In Supporting Neutrogena ‘#1 Recommended’ Advertising

J&J Consumer Protests Process, Findings In Second Industry Self-Regulation Review

Executive Summary

J&J Consumer appeals National Advertising Division decision, arguing a “#1 claim” for its Neutrogena personal care line challenged by L’Oréal USA is materially similar to one that NAD attorneys found it supported more than a decade ago.

You may also be interested in...



Dermatologist Survey Lacked Details, Choices To Support Neutrogena ‘#1 Recommended’ Claim

J&J failed to convince BBB National Program’s appeals panel a 2008 NAD decision supporting its “#1 dermatologist recommended” claim for Neutrogena should preclude another review. Panel says market has changed in 12 years since review of Unilever challenge and L’Oreal could make its own challenge.

Survey Says! J&J Prevails Over L’Oreal In NAD ‘#1 Dermatologist Recommended’ Dispute

L’Oreal USA will appeal a National Advertising Division decision advising it to stop claiming that CeraVe is the “#1 dermatologist recommended skincare brand.” J&J challenged the claim, taking issue with the underlying dermatologist survey.

NAD Offers Complex And Fast Tracks: Not All Advertising Claim Reviews Are Alike

NAD will assign three attorneys at the beginning of each Complex Track review instead of one, director Laura Brett said in a recent interview. The industry self-regulation group also recently launched its Fast-Track program for more simple ad claim challenges that rarely have been made.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS151500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel